VAXIMM Announces Results from VXM01 Phase I/II Combination Trial with PD-L1 Inhibitor Avelumab to be Presented at ASCO20

by | May 14, 2020

14 May 2020, VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the safety run-in results from a Phase I/II study in progressive glioblastoma with its lead product candidate, oral VXM01, in combination with the PD-L1 inhibitor avelumab are being presented as an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Meeting being held May 29-31, 2020.


Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner